Brainsway widens treatment scope for its Deep TMS system


Brainsway has received the CE mark for its Deep TMS (transcranial magnetic stimulation) system to treat neuropathic chronic pain in the EU and the countries in Asia and Latin America that recognise the CE mark. Neuropathic pain is the sixth indication for which Deep TMS has achieved CE mark approval, the others being for clinical depression, bi-polar disorder, schizophrenia (negative symptoms), Parkinson's diseases and post-traumatic stress disorder.

This article is tagged to:
Sector: Medical Devices
Geography: Israel

Access all of our latest analysis, data and forecasts - request a trial